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Abstract
Background: The antithyroid thioureylenes, propylthiouracil (PTU) and methimazole (MMI), are
effective in the treatment of patients with plaque psoriasis. The mechanism of action of the drugs
in psoriasis is unknown. Since the drugs reduce circulating IL-12 levels in patients with Graves'
hyperthyroidism, the effect of propylthiouracil on CD1a expression in psoriatic lesions was
examined in biopsy samples of patients with plaque psoriasis. CD1a is a marker of differentiated
skin antigen presenting cells (APC, Langerhans cells). Langerhans cells and skin monocyte/
macrophages are the source of IL-12, a key cytokine involved in the events that lead to formation
of the psoriatic plaque.
Methods: Biopsy specimens were obtained from six patients with plaque psoriasis who were
treated with 300 mg propylthiouracil (PTU) daily for three months. Clinical response to PTU as
assessed by PASI scores, histological changes after treatment, and CD1a expression in lesional skin
before and after treatment were studied.
Results: Despite significant improvement in clinical and histological parameters the expression of
CD1a staining cells in the epidermis did not decline with propylthiouracil treatment.
Conclusions: It appears that the beneficial effect of propylthiouracil in psoriasis is mediated by
mechanisms other than by depletion of skin antigen-presenting cells.
Background
Psoriasis is a common skin disorder affecting 1 to 3 per-
cent of the world's population.[1,2] Treatment of the dis-
ease results in costs that range between 0.7 to more than
4 billion dollars annually in the US alone [3]. One of the
most cost-effective forms of potential treatment for the
disease is the use of antithyroid thioureylenes such a pro-
pylthiouracil. We previously reported the effectiveness of
thioureylene treatment in patients with plaque psoriasis
[4–7], a finding since confirmed by others [8]. The mech-
anism of action of antithyroid thioureylenes in psoriasis
remains unclear. The drugs have been studied with rela-
tion to their effect in Graves' hyperthyroidism which, like
psoriasis, is an autoimmune disorder [9–12] Antithyroid
thioureylenes, of which propylthiouracil, methimazole
and carbimazole are used in clinical practice, have known
immunomodulatory properties [13,14] and, in the case of
psoriasis, also have antiproliferative effects as demon-
strated by their ability to produce a decline in markers of
cellular proliferation such as proliferative cell nuclear
antigen (PCNA)[15].
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Skin antigen-presenting cells (Langerhans cells) appear to
play an important role in the initiating events that lead to
the cytokine cascade that results in keratinocyte prolifera-
tion and development of psoriatic lesions [16–18]. Effec-
tive therapeutic approaches to psoriasis treatment, such as
psoralen UV-A therapy (PUVA), which result in depletion
of APCs in the skin [19,20], and UV-B [21], lead to one of
the most sustained improvement in psoriasis. IL-12, a
product of Langerhans cells and skin monocytes plays a
pivotal role in T-cell activation that leads to formation of
the psoriatic plaque [22]. IL-12 levels are also significantly
raised in patients with Graves' hyperthyroidism and are
reduced following treatment with propylthiouracil [23].
CD1a is expressed in differentiated antigen-presenting
cells and monocytes and is used as a marker for the pres-
ence of these cells in the skin[24–26]. The CD1 molecules
are the products of five CD1 genes located on chromo-
some 1. The genes are closely related to the mixed histo-
compatibilty complex (MHC) genes indicating origin
from a common precursor [27]. CD1 molecules, however,
have limited sequence homology to MHC class I and II
molecules, and unlike the MHC molecules are also capa-
ble of binding non-protein antigens [28,29].
The present study was performed to examine the effect of
propylthiouracil treatment of patients with plaque psoria-
sis on CD1a expression in their psoriatic lesions in order
to determine whether this form of therapy resulted in
depletion of APCs from affected skin, that could account
for the therapeutic benefit of PTU in this disorder.
Methods
Patients
Six patients (4M, 2F) with stable plaque psoriasis were
recruited for study. The patients ranged in age from 21 to
63 years, mean ± SD, 44 ± 16 years. None of the patients
was taking any form of topical or systemic treatment,
other than emollients, for psoriasis for at least six weeks
prior to entry into the study. Pregnant women and
patients with thyroid dysfunction determined by pre-
enrollment screening thyroid function tests were excluded
from the study. The Institutional Review Board of the Uni-
versity of California, Irvine, approved the study.
Clinical Scoring
Clinical evaluation was performed by the same dermatol-
ogist (VSN) at the time of patient entry into the study and
monthly intervals until completion of the study. Scoring
was based on the PASI scoring system [30].
Biopsy Samples
Biopsy samples were taken from patients at the start and
after 3 months of PTU treatment from the same psoriatic
lesion. Skin samples were obtained using a 5 mm punch
biopsy under aseptic conditions with local anesthesia. The
biopsies were frozen and stored at -70°C until processed.
Indirect immunoperoxidase staining was used to identify
CD1a.
Histological Scoring
Biopsy specimens were viewed by a dermatopathologist
(RJB). Histological scoring was made with a 5-point scor-
ing system graded from 0 to 4 (0 = normal, 1 = slight, 2 -
moderate, 3 = severe, 4 = very severe) based on criteria
noted below after examination of four consecutive high-
power fields. Histological scoring took into account
hypogranulosis, parakeratosis and the inflammatory infil-
trate in the epidermis and superficial dermis. The total
score reported was the sum of the individual parameters.
Epidermal hyperplasia was measured with an oculomi-
crometer from top of the epidermis to the base of the
ridges.
Laboratory Tests
Thyroid function tests were performed in all volunteers
prior to entry into the study and again at monthly inter-
vals until study completion at twelve weeks. The tests con-
sisted of measurement of serum free T4 (FT4) and thyroid-
stimulating hormone (TSH). Complete blood counts
(CBC) were also obtained at the same time intervals.
Immunoperoxidase Staining
Tissue samples from biopsy specimens stored at -70°C
were taken and embedded in paraffin. 4 µm sections were
coated onto slides and allowed to dry overnight at 55°C.
An RBC block (2.5 ml, 30% H2O2 in 100 ml methanol)
was applied for 40 min after which the slides were washed
in tap water until clean. Following a series of washing with
PBS, the slides were washed with blocking serum (5%
horse serum) for 20 min after which antibody for CD1a
(1:100 dilution) was applied for 30 minutes. The slides
were washed with PBS for 5 min after which anti-mouse
antibody (1:200 dilution) was applied and the slides
washed again in PBS for 5 minutes. Tertiary antibody
(ABC kit) was added for 30 min and the slides were then
washed for with PBS. DAB was applied in the dark (10
min), the slides were washed in distilled water (5 min),
counterstained with hematoxylin, washed with tap water,
dehydrated and mounted.
Quantification
Results were expressed as the absolute number of positive
staining dendritic cells counted over a 1 mm length of the
epidermis. Only cells with clearly defined nuclei present
in the suprabasal layers of the epidermis were counted.BMC Dermatology 2003, 3 http://www.biomedcentral.com/1471-5945/3/3
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Statistical Analysis
The results are expressed as mean ± SD. Statistical analysis
was performed using the t-test for paired observations.
Level of significance was p < 0.05.
Results
Clinical Response and PASI Scores
All patients showed some improvement in their psoriasis
with near-complete resolution in 4 patients. PASI scores
declined from 21.40 ± 6.81 at baseline to 7.85 ± 4.35 at
completion of the study (p < 0.004). Clinical improve-
ment became apparent about three weeks after therapy.
Histological Scores
Histological scores also declined significantly from 7.17 ±
2.78 at baseline to 3.00 ± 2.61 at the end of 12 weeks PTU
treatment (p < 002). Epidermal thickness decreased from
0.52 ± 0.17 mm to 0.26 ± 1.11 mm (p < 0.007).
Serum TSH, FT4 and CBC
CBC remained normal (7.85 ± 0.53 vs. 8.05 ± 1.31 cells/
µL, p = ns) during the entire study with no patient dem-
onstrating any leucopenia. Serum TSH concentrations
remained within the euthyroid range with no patient
exhibiting clinical signs or offering complaints suggestive
of hypothyroidism. Serum free thyroxine (FT4) showed no
significant change. Serum TSH slowed a slight rise in some
patients with the group as a whole showing no significant
elevation of TSH (1.72 ± 0.98 µU/ml vs. 2.73 ± 1.43 µU/
ml, p = ns). The rise did not exceed the normal range, and
all patients remained clinically euthyroid.
CD1a staining Langerhans cells before treatment with 300 mg propylthiouracil for 12 weeks Figure 1
CD1a staining Langerhans cells before treatment with 300 mg propylthiouracil for 12 weeksBMC Dermatology 2003, 3 http://www.biomedcentral.com/1471-5945/3/3
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Expression of CD1a in Psoriatic Plaques
As expected, CD-1a with characteristic stellate profiles typ-
ical for Langerhans cells were readily seen in the epidermis
in all pre- and post-treatment biopsy samples. The
number of CD-1a staining cells showed an apparent
increase after propylthiouracil therapy. The number of
such cells rose from 5.67 ± 4.08 pretreatment to 10.00 ±
4.20 post-treatment (P < 0.02) (Fig 1, 2).
Discussion
The efficacy of antithyroid thioureylenes as agents in the
treatment of plaque psoriasis is well established [4,5,7,8]
The mechanism of action of these agents in psoriasis
remains unclear. The drugs can potentially act by reducing
the cytokine signals that lead to keratinocyte proliferation
or by reducing keratinocyte proliferation. A key element
in the generation of the cytokine signals responsible for
formation of a psoriatic plaque is the skin antigen-pre-
senting cell or Langerhans cell. Therapeutic modalities
deplete such cells, that often lead to improvement in pso-
riasis. The best example of such an approach is treatment
with UV-A and psoralens, as well as UV-B, which result in
depletion of APCs and produce one of the most long-last-
ing remissions of the disease which might last in some
instances for as long as 6 months [31,32] A key antigenic
marker of skin APCs is CD1a. Langerhans cell precursors
arise from CD34 positive monocytes/macrophages in the
marrow [33,34]. They circulate in the blood before local-
izing in the skin, primarily in dermal connective tissue. In
the dermis, the Langerhans precursors are strongly HLA-
DR (Ia) positive, and are relatively non-phagocytic, "inde-
terminate cells." CD1a expression is not pronounced in
CDla staining Langerhans cells after treatment with 300mg propylthiouracil for 12 weeks. Figure 2
CDla staining Langerhans cells after treatment with 300mg propylthiouracil for 12 weeks.BMC Dermatology 2003, 3 http://www.biomedcentral.com/1471-5945/3/3
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the precursors and is not significantly expressed until the
cells become differentiated.[35–38] Differentiated cells
localize to the midepidermis, demonstrate characteristic
Birbeck granules, and exhibit dendritic appendages. These
differentiated cells, although usually stable, sometime
exhibit proliferative activity and increase in many cutane-
ous immune response states [23,39,40]. The inability of
PTU to reduce CD1a expression in biopsy samples of
patients with psoriasis suggests that the mechanism of
action of this drug is psoriasis is not due to any effect on
skin antigen-presenting cells or production of IL-12, a
motive cytokine that is responsible for initiation and
maintenance of the cytokine stimulatory cascade that
leads to formation of the psoriatic plaque [16]. In support
of this argument is the fact that circulating IL-12 did not
show any significant change with PTU treatment (submit-
ted). Additional studies are being performed which
address whether PTU treatment of patients with plaque
psoriasis leads to reduced in situ IL-12 expression, alters
production of the IL-35 or IL-40 components of the IL-70
heterodimer, as well as exerts an effect by enhancing
apoptosis in the proliferated keratinocytes that make up
the psoriatic plaque which would result in clinical
improvement.
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